PKC Inhibitor Compounds Isozyme Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by protein kinase C (PKC) activity lack effective inhibitors that can specifically target PKC isozymes, leading to inadequate management of conditions such as autoimmune diseases, inflammatory disorders, and cancer.
Innovation Solution
Development of compounds represented by formula (I), which are designed to inhibit PKC activity by targeting specific isozymes, thereby providing therapeutic benefits for various diseases associated with PKC activity, including autoimmune diseases and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific PKC inhibitors are used, then PKC activity is inhibited, but lack of selectivity leads to inadequate treatment effectiveness and increased side effects
Solution Approach 1:
The patent applies local quality by designing PKC inhibitors with specific molecular structures (formula I) that target particular PKC isozymes (such as PKCβ, PKCε, PKCη, PKCθ) rather than inhibiting all PKC isoforms non-selectively. This selective targeting allows the inhibitor to exert its therapeutic effect on specific disease-related isozymes while sparing other isozymes, thereby improving treatment effectiveness and reducing side effects associated with non-specific inhibition.
2Adaptability or versatility
If PKC isozyme-specific inhibitors are developed, then treatment selectivity is improved, but compound complexity and development difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the PKC inhibitor family into distinct structural series, each targeting specific isozyme subsets. The general formula I framework is segmented into specific embodiments (I-1, I-2, etc.) with different substituent patterns that confer selectivity for particular isozymes. This segmentation allows systematic development and optimization of isozyme-specific inhibitors while maintaining a unified design philosophy, thereby managing complexity through structured approach.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying molecular parameters (substituents R1-R6, ring sizes, stereochemistry) within formula I to achieve isozyme selectivity. By adjusting these parameters, the patent generates a library of compounds with different binding affinities and selectivities for various PKC isozymes, enabling optimization of therapeutic profiles without requiring entirely new molecular architectures.
Data Source
AI summary
This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.